Par Pharmaceutical, Inc. manufactures, markets and/or distributes more than 124 drugs in the U.S.

Par, among the top leaders in the U.S. generics industry, possesses a portfolio that includes sterile injectables, alternative dosage forms and many other differentiated products. Par is...

While we are retiring the Par Pharmaceutical and Par Sterile Products names, we remain committed to maintaining our established reputation of reliability, quality products; innovation …

May 18, 2015 · Endo International plc (NASDAQ: ENDP) (TSX: ENL) and Par Pharmaceutical Holdings, Inc. today announced that they have entered into a definitive agreement under …

We’ve earned a reputation as a reliable and trusted specialty pharmaceutical leader, thanks to our patient-centric product development, solution-oriented business partnerships, and novel …

Since 1978, Par Pharmaceutical has been at the forefront of developing, manufacturing, marketing and distributing safe, innovative and cost-effective pharmaceuticals that help …

Jul 20, 2012 · Private equity-firm, TPG Capital, has entered into a definitive agreement to acquire US-based Par Pharmaceutical for US $1.9 billion. Under terms of the agreement, Par …

Par Pharmaceutical Companies, Inc., formerly Pharmaceutical Resources, Inc., develops, manufactures, and distributes a broad line of more than 170 generic drug products (an …

Sep 28, 2015 · Ireland-based Endo International has completed the $8.05bn acquisition of US-based Par Pharmaceutical Holdings from private investment firm TPG Capital North America. …

Sep 28, 2015 · Endo's combined U.S. Generics segment, which includes Par Pharmaceutical and Qualitest, will be named Par Pharmaceutical, an Endo International Company and will be led …